Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 30, 2006
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which markets contact lenses, and CooperSurgical (CSI), which manufactures medical devices for gynecologists and obstetricians. The reporting period includes the integration of the Ocular Sciences, Inc. acquisition (completed Jan 2005) and smaller acquisitions of Inlet Medical and NeoSurg Technologies in late 2005.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Apr 30, 2006 |
Three Months Ended Apr 30, 2005 |
Six Months Ended Apr 30, 2006 |
Six Months Ended Apr 30, 2005 |
|---|---|---|---|---|
| Net Sales | $211,397 | $215,494 | $417,136 | $363,044 |
| Gross Profit | $131,363 | $130,709 | $260,524 | $222,827 |
| Gross Margin % | 62.1% | 60.7% | 62.5% | 61.4% |
| Operating Income | $24,480 | $40,747 | $58,194 | $67,364 |
| Net Income | $13,701 | $27,827 | $31,655 | $45,536 |
| Diluted EPS | $0.30 | $0.59 | $0.69 | $1.06 |
| Cash from Operations (6mo) | N/A | $78,452 | $78,683 | |
| Cash & Equivalents (End) | N/A | $16,555 | $17,119 | |
| Total Debt | N/A | $756,807 | $704,912 |
Note: Debt figures represent total funded indebtedness (Short-term + Long-term). Cash flow figures are for the six-month period.
Material Changes vs. Prior Period
- Revenue: Net sales decreased 2% in the quarter but increased 15% year-to-date (YTD). The YTD growth was driven by the inclusion of Ocular Sciences for a full six months and organic growth in CooperSurgical (+13% YTD). CooperVision sales declined 4% in the quarter due to supply constraints in Japan and unfavorable currency impacts.
- Profitability: Operating income dropped 40% in the quarter and 14% YTD. This decline is attributed to increased Selling, General, and Administrative (SGA) expenses (up 11% in the quarter) and higher Research and Development (R&D) costs.
- Expenses:
- SGA: Increased significantly due to $3.1 million in stock-based compensation (new accounting standard SFAS 123R), restructuring costs, and litigation expenses.
- R&D: Increased 160% in the quarter and 142% YTD, largely due to a $7.5 million charge for acquired in-process research and development (IPR&D) from the NeoSurg acquisition.
- Tax Rate: The effective tax rate decreased to 11.4% YTD from 21% in the prior year, reflecting a shift of business to lower-tax jurisdictions.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Product Strategy: The Company is focusing on launching silicone hydrogel contact lenses and expanding its PC Technology product line. It plans to phase out corneal health products to focus specifically on contact lenses.
- Capital Expenditures: Expected to be $150-$160 million for fiscal 2006, primarily for manufacturing capacity expansion and distribution center consolidation.
- Liquidity: Management believes cash on hand ($16.6 million) plus operating cash flow will fund operations. The Company has $148.7 million available under its amended $750 million credit facility.
Risks and Contingencies
- Legal Proceedings:
- Securities Litigation: Three consolidated class-action lawsuits allege improper accounting for the Ocular acquisition and inflated earnings guidance. The Company intends to vigorously defend these matters.
- Derivative Suits: Multiple shareholder derivative actions allege breach of fiduciary duty and mismanagement regarding the Ocular merger.
- Patent Litigation: Ongoing disputes with Bausch & Lomb (infringement claims) and CIBA Vision (declaratory judgment filed by CooperVision regarding Biofinity lenses).
- Tax Litigation: The IRS has asserted a deficiency of $44.8 million plus penalties regarding Ocular's transfer pricing for tax years 1999-2001. The Company contests this and believes the outcome will not be materially adverse.
- Integration Risks: Risks associated with integrating Ocular, Inlet, and NeoSurg, including potential delays in realizing synergies and manufacturing inefficiencies.
Investor Verification Checklist
- Stock-Based Compensation Impact: Verify the full-year impact of the new SFAS 123R accounting standard on net income, as it reduced reported income by $6.1 million in the first six months.
- Restructuring Costs: Monitor the execution of the $25-$30 million integration plan for the Ocular acquisition, specifically regarding facility shutdowns and severance.
- Legal Exposure: Track the status of the consolidated securities class action and the IRS tax dispute, as these represent significant contingent liabilities.
- Silicone Hydrogel Launch: Assess the timeline and market acceptance of the new silicone hydrogel products, which are critical for future growth against competitors.
- Debt Covenants: Confirm continued compliance with the amended credit facility covenants, specifically the leverage ratio (currently 3.2:1) and fixed charge coverage ratio.